Weiwei Zhang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Aqueous Solution

Randomized Controlled Trial

Top Venues

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Yun Liu, Wei Wang, Hongjie Qian, Yuzhou Gui, Yating Wang, Rong Song, Qian Chen, Eric Rowinsky, Sheng Wang, Xiaoguang Liang, Kaicun Gu, Bo Zhou, Weiwei Zhang, Liqin Zhang, Chen Yu, Jingying Jia
Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist. Clinical and translational science 17 (3) (2024)
Yun Liu, Wei Wang, Hongjie Qian, Yuzhou Gui, Yating Wang, Rong Song, Qian Chen, Eric Rowinsky, Sheng Wang, Xiaoguang Liang, Kaicun Gu, Bo Zhou, Weiwei Zhang, Liqin Zhang, Chen Yu, Jingying Jia
Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist. Clinical and translational science 17 (3) (2024)
Yun Liu, Wei Wang, Hongjie Qian, Yuzhou Gui, Yating Wang, Rong Song, Qian Chen, Eric Rowinsky, Sheng Wang, Xiaoguang Liang, Kaicun Gu, Bo Zhou, Weiwei Zhang, Liqin Zhang, Chen Yu, Jingying Jia
Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist. Clinical and translational science 17 (3) (2024)
Yun Liu, Wei Wang, Hongjie Qian, Yuzhou Gui, Yating Wang, Rong Song, Qian Chen, Eric Rowinsky, Sheng Wang, Xiaoguang Liang, Kaicun Gu, Bo Zhou, Weiwei Zhang, Liqin Zhang, Chen Yu, Jingying Jia
Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin-A receptor antagonist. Clinical and translational science 17 (3) (2024)